Advanced in Ovarian Carcinosarcoma

Dr. James S. Hoffman

Gynecologic Oncology
3300 Main Street, 
Springfield, MA 
Advanced in Ovarian Carcinosarcoma
3300 Main Street, 
Springfield, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Hoffman is a Gynecologic Oncologist in Springfield, Massachusetts. Dr. Hoffman is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Malignant Mixed Mullerian Tumor, Ovarian Cancer, Endometrial Cancer, and Sertoli-Leydig Cell Tumor.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

3300 Main Street, Springfield, MA 01107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 6 Less Clinical Trials

8 Total Publications

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Journal: Gynecologic oncology
Published: August 17, 2016
Similar Doctors
Elite in Ovarian Carcinosarcoma
Dr. Masoud Azodi
Gynecologic Oncology | Oncology
Elite in Ovarian Carcinosarcoma
Dr. Masoud Azodi
Gynecologic Oncology | Oncology

Yale University

20 York St, 
New Haven, CT 
 (59.0 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Masoud Azodi is a Gynecologic Oncologist and an Oncologist in New Haven, Connecticut. Dr. Azodi is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy.

Elite in Ovarian Carcinosarcoma
Dr. Gary H. Altwerger
Gynecologic Oncology | Obstetrics and Gynecology
Elite in Ovarian Carcinosarcoma
Dr. Gary H. Altwerger
Gynecologic Oncology | Obstetrics and Gynecology

Yale University

20 York St, 
New Haven, CT 
 (59.0 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Altwerger is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New Haven, Connecticut. Dr. Altwerger is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hormone Replacement Therapy (HRT), and Hysterectomy.

Elite in Ovarian Carcinosarcoma
Dr. Gloria S. Huang
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Ovarian Carcinosarcoma
Dr. Gloria S. Huang
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Smilow Cancer Center Hospital At Yale New Haven, 20 York Street, 
New Haven, CT 
 (59.0 miles away)
203-200-4176
Languages Spoken:
English
See accepted insurances

Gloria Huang is a Gynecologic Oncologist and an Oncologist in New Haven, Connecticut. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, and Adult Soft Tissue Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile